Literature DB >> 10811846

Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.

T Fushimi1, A Kojima, M A Moore, R G Crystal.   

Abstract

Dendritic cells (DCs) are powerful antigen-presenting cells that function as the principal activators of T cells. Since the human CC chemokine, macrophage inflammatory protein 3alpha (MIP-3alpha), is chemotactic for DCs in vitro, we hypothesized that adenovirus-mediated gene transfer of MIP-3alpha (AdMIP-3alpha) to tumors might induce local accumulation of DCs and inhibit growth of preexisting tumors. AdMIP-3alpha directed expression of mRNA and protein in vitro, and the supernatant of A549 cells infected with AdMIP-3alpha was chemotactic for DCs. In vivo, injection of AdMIP-3alpha into subcutaneous tumors resulted in local expression of the MIP-3alpha cDNA and in the local accumulation of DCs. In four syngeneic tumor models, growth of established tumors was significantly inhibited compared with untreated tumors or tumors injected with control vector, and in all but the poorly immunogenic LLC carcinoma model, this treatment increased survival advantage of the preexisting tumors. In all four tumor models, intratumoral injection of AdMIP-3alpha induced the local accumulation of CD8b. 2(+) cells and elicited tumor-specific cytotoxic T-lymphocyte activity, and adoptive transfer of splenocytes of animals receiving this treatment protected against a subsequent challenge with the identical tumor cells. In wild-type but not in CD8-deficient mice, AdMIP-3alpha inhibited the growth of tumors. Finally, AdMIP-3alpha also inhibited the growth of distant tumors. This strategy may be useful for enlisting the help of DCs to boost anti-tumor immunity against local and metastatic tumors without the necessity of ex vivo isolation and manipulation of DCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811846      PMCID: PMC315459          DOI: 10.1172/JCI7548

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

Review 1.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

2.  Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration.

Authors:  M Cumberbatch; R J Dearman; I Kimber
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

3.  Induction of antitumor immunity using bone marrow-generated dendritic cells.

Authors:  A Porgador; D Snyder; E Gilboa
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

4.  Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells.

Authors:  J Gong; L Chen; D Chen; M Kashiwaba; Y Manome; T Tanaka; D Kufe
Journal:  Gene Ther       Date:  1997-10       Impact factor: 5.250

5.  FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.

Authors:  C Esche; V M Subbotin; C Maliszewski; M T Lotze; M R Shurin
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

6.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.

Authors:  M L Albert; B Sauter; N Bhardwaj
Journal:  Nature       Date:  1998-03-05       Impact factor: 49.962

7.  Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection.

Authors:  C M Celluzzi; L D Falo
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

8.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors:  F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

9.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.

Authors:  J I Mayordomo; D J Loftus; H Sakamoto; C M De Cesare; P M Appasamy; M T Lotze; W J Storkus; E Appella; A B DeLeo
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

10.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Authors:  P Paglia; C Chiodoni; M Rodolfo; M P Colombo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  33 in total

1.  High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.

Authors:  Xiangjiu Ding; Kexin Wang; Hui Wang; Guangyong Zhang; Yajing Liu; Qingyun Yang; Weijie Chen; Sanyuan Hu
Journal:  J Gastrointest Surg       Date:  2011-11-10       Impact factor: 3.452

Review 2.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

3.  Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis.

Authors:  Jin-Yue Hu; Guan-Cheng Li; Wen-Meng Wang; Jian-Gao Zhu; Yue-Fei Li; Guo-Hua Zhou; Qu-Bing Sun
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

Review 4.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 5.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

6.  Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Mathias Wagner; Christina Weber; Bianca Kruse; Katja Kempf; Jochen König; Bettina Rau; Martin Schilling
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

7.  Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes.

Authors:  Feng-Ying Huang; Jing Lei; Yan Sun; Fei Yan; Bin Chen; Liming Zhang; Zhuoxuan Lu; Rong Cao; Ying-Ying Lin; Cai-Chun Wang; Guang-Hong Tan
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

8.  Local hyperthermia decreases the expression of CCL-20 in condyloma acuminatum.

Authors:  Xiaoqin Wang; Xing-Hua Gao; Yuxiao Hong; Xiaodong Li; Hong-Duo Chen
Journal:  Virol J       Date:  2010-11-04       Impact factor: 4.099

Review 9.  Chemokines and the microenvironment in neuroectodermal tumor-host interaction.

Authors:  Rajasekharan Somasundaram; Dorothee Herlyn
Journal:  Semin Cancer Biol       Date:  2008-11-13       Impact factor: 15.707

10.  Interaction between CXCR4 and CCL20 pathways regulates tumor growth.

Authors:  Katia Beider; Michal Abraham; Michal Begin; Hanna Wald; Ido D Weiss; Ori Wald; Eli Pikarsky; Rinat Abramovitch; Evelyne Zeira; Eithan Galun; Arnon Nagler; Amnon Peled
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.